We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Celldex Therapeutics (CLDX - Free Report) closed at $5.92 in the latest trading session, marking a -1.17% move from the prior day. This change lagged the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 0.7%, and the Nasdaq, a tech-heavy index, added 0.91%.
Heading into today, shares of the biopharmaceutical company had gained 27.44% over the past month, outpacing the Medical sector's gain of 2.07% and the S&P 500's gain of 4.16% in that time.
Investors will be hoping for strength from CLDX as it approaches its next earnings release. In that report, analysts expect CLDX to post earnings of -$1.20 per share. This would mark year-over-year growth of 52.94%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.46 million, down 57.8% from the year-ago period.
Investors should also note any recent changes to analyst estimates for CLDX. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CLDX is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 69, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know
Celldex Therapeutics (CLDX - Free Report) closed at $5.92 in the latest trading session, marking a -1.17% move from the prior day. This change lagged the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 0.7%, and the Nasdaq, a tech-heavy index, added 0.91%.
Heading into today, shares of the biopharmaceutical company had gained 27.44% over the past month, outpacing the Medical sector's gain of 2.07% and the S&P 500's gain of 4.16% in that time.
Investors will be hoping for strength from CLDX as it approaches its next earnings release. In that report, analysts expect CLDX to post earnings of -$1.20 per share. This would mark year-over-year growth of 52.94%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.46 million, down 57.8% from the year-ago period.
Investors should also note any recent changes to analyst estimates for CLDX. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CLDX is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 69, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.